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Abstract
Background: Acute left-sided colonic obstruction is most often caused by malignancy and the
surgical treatment is associated with a high mortality and morbidity rate. Moreover, these operated
patients end up with a temporary or permanent stoma. Initial insertion of an enteral stent to
decompress the obstructed colon, allowing for surgery to be performed electively, is gaining
popularity. In uncontrolled studies stent placement before elective surgery has been suggested to
decrease mortality, morbidity and number of colostomies. However stent perforation can lead to
peritoneal tumor spill, changing a potentially curable disease in an incurable one. Therefore it is of
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BMC Surgery 2007, 7:12 http://www.biomedcentral.com/1471-2482/7/12paramount importance to compare the outcomes of colonic stenting followed by elective surgery
with emergency surgery for the management of acute left-sided malignant colonic obstruction in a
randomized multicenter fashion.
Methods/design: Patients with acute left-sided malignant colonic obstruction eligible for this
study will be randomized to either emergency surgery (current standard treatment) or colonic
stenting as bridge to elective surgery. Outcome measurements are effectiveness and costs of both
strategies. Effectiveness will be evaluated in terms of quality of life, morbidity and mortality. Quality
of life will be measured with standardized questionnaires (EORTC QLQ-C30, EORTC QLQ-CR38,
EQ-5D and EQ-VAS). Morbidity is defined as every event leading to hospital admission or
prolonging hospital stay. Mortality will be analyzed as total mortality as well as procedure-related
mortality. The total costs of treatment will be evaluated by counting volumes and calculating unit
prices. Including 120 patients on a 1:1 basis will have 80% power to detect an effect size of 0.5 on
the EORTC QLQ-C30 global health scale, using a two group t-test with a 0.05 two-sided
significance level. Differences in quality of life and morbidity will be analyzed using mixed-models
repeated measures analysis of variance. Mortality will be compared using Kaplan-Meier curves and
log-rank statistics.
Discussion: The Stent-in 2 study is a randomized controlled multicenter trial that will provide
evidence whether or not colonic stenting as bridge to surgery is to be performed in patients with
acute left-sided colonic obstruction.
Trial registration: Current Controlled Trials ISRCTN46462267.
Background
Colorectal cancer is the second most common cancer in
women and the third most common in men in the Neth-
erlands [1]. The incidence in the Netherlands in 2003 was
9898 new cases, men and women were equally affected
(Dutch Cancer Registry) [2]. Literature shows that
between 7 and 29% of the patients present with a sub-
total or total bowel obstruction [3,4].
Conventionally these patients are treated with emergency
surgery to restore luminal patency. These emergency oper-
ations, involving an unprepared and obstructed bowel,
include a variety of procedures ranging from a loop colos-
tomy (blow-hole) to a Hartmann's procedure or even a
subtotal colectomy. These interventions have a mortality
rate of 15–34% and a morbidity rate of 32–64% despite
advances in perioperative care [4-8]. It is well recognized
that in a considerable number of these patients the osto-
mies will not be closed because of old age, metastatic dis-
ease or poor condition [3,7]. Patients with a permanent
stoma do report a significant lower health-related quality
of life than comparable patients without colostomy and
require costly stoma material [9-12].
Since the early 1990s colonic stenting has been intro-
duced, mainly in the left-sided colon, to restore luminal
patency. It can be applied as a preoperative treatment to
prepare patients for elective surgery as well as a definitive
palliative procedure in patients with incurable disease
[13]. In uncontrolled studies stent placement before elec-
tive surgery has been suggested to improve the patients'
clinical condition, decreasing mortality, morbidity and
number of colostomies [4,5,7,8]. Additionally this tem-
porary procedure gives the opportunity to perform accu-
rate tumor staging, leading to avoidance of surgery in
patients with disseminated disease or unacceptable surgi-
cal risk [7,14-16]. In these patients the colonic stent may
serve as permanent palliation. Colonic stenting also cre-
ates the opportunity to give neo-adjuvant therapy,
improving patients' prognosis.
A systematic review by Sebastian et al. of 54 uncontrolled
trials and case reports on placement of self-expandable
metal stents revealed a technical success rate of 90–100%,
a clinical success rate of 84–94% and clinical success
when used as bridge to surgery of 71.7%. Major complica-
tions related to stent placement include perforation (4%),
stent migration (11.8%) and re-obstruction (7.3%), caus-
ing a cumulative mortality of 0.58% [13]. It has to be
underlined that stent perforation can lead to peritoneal
tumor spill, changing a potentially curable disease in an
incurable one. Minor complications like rectal bleeding
(5%), transient anorectal pain (5%) and fecal impaction
can mostly be managed conservatively [17,18].
The overall influence of colonic stenting on patient's qual-
ity of life is unknown. It is important to realize that stent-
ing so far has mainly been done by experts and the
published results are mostly uncontrolled, subjective to
selection bias and do not include the learning curves.Page 2 of 7
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with self-expandable stents before elective surgery and
emergency surgery for malignant acute colorectal obstruc-
tion has not been published. We propose to compare
these two treatment algorithms in a prospective multi-
center randomized setting in terms of effectiveness (pri-
mary outcome measure) and healthcare costs.
Methods/design
Study objectives
To compare, in a prospective randomized fashion, colonic
stenting followed by elective surgery with emergency sur-
gery for the management of acute left-sided malignant
colonic obstruction in terms of effectiveness. Effectiveness
will be evaluated in terms of quality of life, morbidity and
mortality.
Study design
The Stent-in 2 study is a randomized multicenter trial with
4 academic and 11 regional hospitals participating in the
project. Patients presenting with confirmed acute left-
sided malignant colonic obstruction will be asked for
informed consent if the inclusion and exclusion criteria
are met. Computerized randomization will take place
after informed consent has been obtained. Randomiza-
tion will be performed centrally at the Academic Medical
Center, using computer-generated lists prepared by the
Department of Clinical Epidemiology and Bio-statistics.
Lists will be constructed with randomly permuted blocks
per stratum, in which strata will be defined by center (par-
ticipating hospital). Patients will be randomized to either
emergency surgery (current standard treatment) or
colonic stenting as bridge to elective surgery (figure 1).
Treatment will be initiated within 24 hours after randomi-
zation.
Study population
The study population consists of patients with acute left-
sided malignant colonic obstruction. Inclusion criteria
are: symptoms of left-sided (colon descendens, sigmoid
or rectum) malignant colonic obstruction existing less
than one week, defined as obstructive symptoms with
dilation of the colon on either plain abdominal X-ray and
typical abnormalities on a gastrografin enema study or
CT-abdomen with contrast compatible with a malignant
colonic stricture; age above 18 years; signed informed
consent. Exclusion criteria are: peritonitis, perforation,
fever, sepsis or other serious complications demanding
urgent surgery; American Society of Anesthesiologists
(ASA) IV or V; obstruction due to non-colonic malignan-
cies or from a benign origin: distal tumor margin less than
10 cm from the anal verge; incapability to complete self-
report quality of life questionnaires.
Outcome parameters
Effectiveness and costs of both strategies will be com-
pared. Effectiveness will be evaluated in terms of quality
of life, morbidity and mortality. Quality of life will be
measured with the following standardized question-
naires: EORTC QLQ-C30 (European Organization for
Research and Treatment of Cancer (EORTC) Quality of
Life Questionnaire C30), the colorectal cancer specific
EORTC QLQ-CR38 (European Organization for Research
and Treatment of Cancer (EORTC) Quality of Life Ques-
tionnaire CR38), the EQ-5D (EuroQol 5 dimensions) and
the EQ-VAS (EuroQol visual analogue scale). Morbidity is
defined as every event leading to hospital admission or
prolonging hospital stay. Mortality will be analyzed as
total mortality as well as procedure-related mortality.
Cost items will include costs of hospital admissions and
readmissions (operation, nursing days, outpatient visits),
institutional care (nursing homes, hospice), home care,
medication and other health care providers as well as
direct non-medical costs (travel expenses).
Participating centers
Fifteen Dutch hospitals including 4 academic and 11 non
academic are currently participating in this trial. Specific
requirement is to assure that enteral stent placement is
performed by an experienced gastroenterologist. Gastro-
enterologists are considered experienced after placement
of at least 20 enteral stents of which 10 colonic. In case no
experienced gastroentorologist is available the patient
should be referred to a nearby hospital with sufficient
experience. The patient can always be referred for stent
placement to the Academic Medical Center in Amsterdam.
Flowchart Stent-in 2 studyigure 1
Flowchart Stent-in 2 study.
Patients with acute left-sided malignant colonic 
obstruction fulfilling the in-/exclusion criteria 
Decline to participate 
Randomization after informed 
consent (N=120)
Emergency surgery (N=60)
In case of colostomie:  
a) Restoration of bowel continuity within 
3-6 months if patient is fit enough 
b) No restoration if patient is not fit enough
Follow-up for 6 months  
Analysis on intention-to-treat basis,  




























Colonic stenting as bridge to elective 
surgery (N=60) 
Dependent on tumor staging:  
b) Incurable disease; stent serves as 
palliative therapy 
b) Curable disease; elective surgery  Page 3 of 7
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if sufficient experience is available (> 20 cases).
Ethics
This study is conducted in accordance with the principles
of the Declaration of Helsinki and 'good clinical practice'
guidelines. The protocol has been approved by the Medi-
cal Ethical Committee of the Academic Medical Center in
Amsterdam and the local Ethical Committees of the par-
ticipating centers. Prior to randomization informed con-
sent will be obtained from all patients.
Study outline
Patients presenting with confirmed acute left-sided malig-
nant colonic obstruction will be asked for informed con-
sent if the inclusion and exclusion criteria are met.
Computerized randomization will take place after written
informed consent has been obtained according to the
Guidelines of Clinical Research in Humans. Randomiza-
tion will be performed centrally at the Academic Medical
Center, using computer-generated lists prepared by the
Department of Clinical Epidemiology and Bio-statistics.
Patients will be randomized to either emergency surgery
or colonic stenting as bridge to elective surgery. Treatment
will be initiated within 24 hours after randomization.
Colonic stenting
A) Material
For this study, the enteral stent which has been most fre-
quently used in clinical studies will be employed (Enteral
Wallstent™ (Boston Scientific, Natick, MA)) [13,18]. This
through-the-scope stent is available in the length of 6 and
9 cm, with a diameter of 22 mm.
B) Procedure
After preparation of the distal colon with an enema,
colonoscopy is performed. In all patients prophylactic
antibiotics will be administered, covering aerobic and
anaerobic bacteria. After endoscopic visualization of the
lesion, biopsies will be taken and the length of the lesion
will be measured (fluoroscopically). In case a normal
colonoscope or sigmoidoscope can transverse the lesion
there is no indication for stent placement and the patient
will be considered a drop out. The obstructive lesion
should not be dilated prior to stent placement. Stents will
always be placed over a guidewire and under fluoroscopic
guidance. A metallic, uncovered, self-expandable stent
will be implanted, at least 3 cm longer (1,5 cm at both
sides) than the lesion. If the stent does not cover the entire
length of the tumor, a second overlapping stent will be
placed. The correct position of the stent will be confirmed
using fluoroscopy and endoscopy.
C) Post-procedure
Successful decompression is defined as restoration of
intestinal transit based on resolution of obstructive symp-
toms on plain abdominal X-ray, production of stools and/
or resolution of nausea and vomiting. If successful decom-
pression is achieved and the condition of the patient is
stabilized, tumor staging of the disease will be performed
(CT-scan/plain chest X-ray) within one week. If any of the
following conditions will be present, patients will be con-
sidered not suitable for surgical therapy and the self-
expandable stent will serve as a palliative therapy: patients
at high risk due to persistent comorbidity, advanced pelvic
disease, peritoneal carcinomatosis and/or unresectable
metastatic lesions. If decompression is not achieved
within time frame of 3 days, or if clinically required,
patients will be treated surgically but will not cross over to
the surgical arm in the analysis.
D) Elective surgery after stenting
Candidates for elective surgery will be operated on after
completion of the preoperative screening, preferably
between day 5 and 14 after inclusion, at the latest four
weeks after inclusion. If possible and convenient, patients
will be discharged between diagnostic work-up and sur-
gery. After preoperative bowel preparation and adminis-
tration of antibiotics both according to the hospital
protocol resection of the tumor will be performed, the
extension of which will be determined by the specific
characteristics of the malignant process. During surgical




Patients will be operated according conventional stand-
ards within 24 hours after randomization. Whether a (pal-
liative) resection or fecal deviation is done is at the
discretion of the surgeon. Surgical options according to
current standards are loop colostomy (blow-hole), resec-
tion with primary anastomosis with or without ileostomy,
Hartmann's procedure, (sub)total colectomy with ileos-
tomy or ileorectal anastomosis.
B) Post-procedure
After emergency surgery when the condition of the patient
is stabilized, tumor staging of the disease will be per-
formed (CT-scan/plain chest X-ray). In case of a colos-
tomy an attempt at restoration of bowel continuity should
preferable be performed within 3–6 months after inclu-
sion. The colostomy will serve as a definitive solution if
the patient refuses a re-operation or when a re-operation
is judged to carry an unacceptable risk (ASA IV of V).Page 4 of 7
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Candidates for surgical re-anastomosis will be operated
on after completion of tumor staging and when consid-
ered stable. If possible and convenient, patients will be
discharged between diagnostic work-up and re-anastomo-
sis.
After preoperative bowel preparation and administration
of antibiotics both according to the hospital protocol a re-




The analysis will be performed in accordance with the
intention to treat principle.
Sample size calculation
Including 120 patients and randomizing them on a 1:1
basis will have 80% power to detect an effect size of 0.5 on
the EORTC QLQ-C30 global health scale, using a two
group t-test with a 0.05 two-sided significance level
[19,20].
An effect size of 0.5 is chosen because a recent systematic
review based on 38 studies, indicated a "remarkable uni-
versality" among estimates of clinical significance that
centered around 0.5 effect size [21]. These authors recom-
mend an effect size of 0.5 to serve as a default value for
clinically significant change on quality of life measures
used with chronic disease patients, when more specific
information is missing, as is the case in patients with
malignant colonic obstruction. Sloan et al. argue that a
0.5 effect size is even a conservative estimate that is likely
to be clinically meaningful [22]. Based on these data we
expect an effect size of 0.5 to be realistic in our group of
patients.
Data collection and monitoring
Patients will be followed for a period of 6 months. The
questionnaires (EORTC QLQ-C30, EORTC QLQ-CR38,
EQ-5D and EQ-VAS) are filled in by the patients on the
day of randomization and on week 4, 12, and 24 after ran-
domization. In addition the patients will be asked to hand
out a small questionnaire on informal care to their car-
egivers on week 4, 12 and 24. The questionnaires will be
sent to the patients by post, collection will be safeguarded
by a trial nurse. The trial nurse will also follow the patients
during their hospital stay after the intervention and con-
tact them by telephone every two weeks to assess compli-
cations, re-interventions, re-admissions, visits to the
outpatient clinic and missing items of the collected qual-
ity of life questionnaires. An electronic Case Record Form
(CRF) will include general patients' data (sex, age, locali-
zation tumor, etc.), patients' responses to quality of life
questionnaires (EORTC QLQ-C30, EORTC QLQ-CR38,
EQ-5D and EQ-VAS), informal care questionnaires and
data concerning type of intervention, complications, mor-
tality, duration of hospital and intensive care stay. This
electronical Case Record Form is based on the paper
source filled out by the treating physician or the patient
him-/herself and put into the data base by a trial nurse.
The trial coordinator will monitor the data of every
included patient.
Data analysis
Differences in quality of life and morbidity will be ana-
lyzed using mixed-models repeated measures analysis of
variance, accounting for differences in survival between
groups. Mortality will be compared using Kaplan-Meier
curves and log-rank statistics.
The primary analysis of the quality of life data will be per-
formed using mixed-models analysis of variances for
repeated measures. Missing data will be handled based on
available data approach.
We will apply an extension of the Q-Twist method to esti-
mate differences in quality-adjusted survival between
groups.
A data and safety monitoring committee will safeguard
trial continuation based on safety and effectiveness data.
They will perform an interim analysis after 60 included
patients have reached a one month follow-up.
Economic evaluation
Health care costs include costs of hospital admissions and
readmissions (operation, nursing days, outpatient visits),
institutional care (nursing homes, hospice), home care,
informal care, medication and other health care providers
as well as direct non-medical costs (travel expenses).
These costs will be estimated for the period after inclusion
until 6 months. Data on hospital care will be collected
from the hospital information systems and CRFs. The par-
ticipating clinicians will fill out CRFs during control visits,
re-interventions and admissions. Use of institutional care,
home care and other health care providers will be col-
lected with a short checklist, used by a special trained
research nurse at 14 days interval until 6 months after
inclusion. Informal care after discharge will be registered
as time spent on informal care giving. This will be meas-
ured using the recall questionnaire as introduced by van
den Berg et al[23]. Those questionnaires will be handed
out by the patients to their caregivers on week 4, 12 and
24 after inclusion.
Real unit costs will be estimated for the surgical interven-
tions and stent placement on the basis of resource use by
detailed measurement of manpower and personnel time,Page 5 of 7
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the microcosting method. Costs of inpatient days in hos-
pital will be estimated as real costs per day using detailed
information from the financial department of the Aca-
demic Medical Center. For all other health care and infor-
mal care, unit costs will be estimated following Dutch
guidelines using fees and standardized costs if considered
representative, and adapted if necessary.
Patient outcome analysis will be expressed by calculating
the costs per quality adjusted life-years (QALYs). For this
calculation the standardized questionnaire (EQ-5D) will
be used as this questionnaire can be translated to utilities
with values from the UK general population.
Final analysis
If the hypothesis holds, a strategy of colonic stenting com-
bined with elective surgery will lead to a better quality of
life, less morbidity, mortality and costs compared with the
standard strategy of emergency surgery. In that case the
effectiveness and costs of both strategies will be reported.
If the alternative strategy turns out to be more effective but
more costly than the standard treatment, the costs per
QALY will be calculated. In a sensitivity analysis, the
impact of the statistical uncertainty of major parameters
in the cost-effectiveness analysis will be examined. Since
costs per patient are typically highly skewed, non-para-
metric bootstrap techniques will be used to derive a 95%
confidence interval for the differences in mean and
median costs.
Discussion
The concept of colonic stenting as bridge to elective sur-
gery in patients with an acute left-sided malignant colonic
obstruction has been developed to reduce the morbidity,
mortality and numbers of colostomies. Although some
might consider stenting as bridge to surgery the preferred
approach, solid evidence is lacking. A previously con-
ducted randomized trial comparing surgery with stenting
for incurable left-sided malignant colonic obstruction had
to be stopped because of an unexpectedly high number of
perforations in the stented group [24]. For this reason, the
Stent-in 2 study is conceived to compare colonic stenting
as bridge to elective surgery with emergency surgery (cur-
rent standard treatment) for the management of acute left-
sided malignant colonic obstruction. This multicenter
randomized study will compare those two strategies with
regard to effectiveness and costs. The aim is to provide evi-
dence whether or not colonic stenting as bridge to surgery
is to be performed in patients with acute left-sided colonic
obstruction.
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